Last kr519.50 DKK
Change Today -11.50 / -2.17%
Volume 330.5K
As of 11:05 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

coloplast-b (COLOB) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/20/15 - kr549.00
52 Week Low
04/14/14 - kr407.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COLOPLAST-B (COLOB)

Related News

No related news articles were found.

coloplast-b (COLOB) Related Businessweek News

No Related Businessweek News Found

coloplast-b (COLOB) Details

Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company offers ostomy care products for intestinal dysfunction resulting from disease, accident, and congenital disorder. Its ostomy care products include colostomy, ileostomy, and urostomy bags under the SenSura brand; and SenSura Mio, a colostomy product with elastic adhesive that fits individual body shapes, as well as ostomy accessories under the Brava brand. The company also provides urology care products for people suffering from diseases and symptoms of the urinary system, such as urinary incontinence, kidney stones, enlarged prostate, impotence, and pelvic floor prolapse, as well as the male reproductive system. Its disposable surgical devices include prostate catheters and stents used for urological and gynaecological applications before, during, and after surgery under the Porgès brand; vaginal slings to restore continence; synthetic mesh products to treat weak pelvic floor; and penile implants for men. In addition, the company provides continence care products comprising SpeediCath catheters that offer catherisation for both genders; and Peristeen, an anal irrigation system for controlled emptying of the bowels. Further, it offers wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products consisting of disinfectant liquids or creams used to protect and treat the skin and to clean wounds. Additionally, Coloplast A/S offers Interdry AG, a textile placed in a skin fold to absorb moisture for the treatment and prevention of skin fold problems, such as fungal infections, damaged skin, or odour nuisance. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies. Coloplast A/S was founded in 1954 and is headquartered in Humlebaek, Denmark.

9,000 Employees
Last Reported Date: 01/29/15
Founded in 1954

coloplast-b (COLOB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr8.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr1.0M
Executive Vice President of Global Operations
Total Annual Compensation: kr1.3M
Executive Vice President of Chronic Care
Total Annual Compensation: kr1.6M
Executive Officer
Total Annual Compensation: kr4.4M
Compensation as of Fiscal Year 2014.

coloplast-b (COLOB) Key Developments

Coloplast Seeks Acquisitions

Coloplast A/S (CPSE:COLO B) is expected to make acquisitions soon. The company confirmed that they are interested in other alternatives than organic growth in order to be able to grow its wound care division that currently generates a below average profit.

Coloplast A/S Announces Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2014; Revised Financial Guidance for the Year 2014 / 2015

Coloplast A/S announced unaudited consolidated earnings results for the first quarter ended December 31, 2014. For the quarter, the company reported revenue of DKK 3,301 million compared to DKK 3,063 million a year ago. Operating profit was DKK 1,076 million compared to DKK 1,013 million a year ago. Profit before tax was DKK 1,048 million compared to DKK 1,040 million a year ago. Net profit for the period was DKK 797 million compared to DKK 780 million a year ago. Diluted EPS was DKK 3.74 compared to DKK 3.63 a year ago. Cash flows from operating activities were DKK 646 million compared to DKK 602 million a year ago. Investments in property, plant and equipment under construction were DKK 136 million compared to DKK 107 million a year ago. The free cash flow amounted to DKK 915 million, a DKK 533 million increase on the same period of last year. EBITDA was DKK 1,194 million compared to DKK 1,119 million a year ago. Return on equity was 55% compared to 49% a year ago. For the year 2014/15, the company expects revenue growth of 8-9% against the previous guidance of 9% at constant exchange rates and 12-13% against previously 11% in DKK. The company continue to expect the EBIT margin to be about 34%, both at constant exchange rates and in DKK. Capital expenditure is still expected to be around DKK 650 million. The effective tax rate is still expected to be around 24%.

Smith & Nephew Denies Sales Rumors

Smith & Nephew plc (LSE:SN.) does not intend to sell its wound care unit to Coloplast A/S (CPSE:COLO B), Olivier Bohoun, Chief Executive Officer of Smith & Nephew told financial and corporate intelligence provider Mergermarket. Bohoun denied rumors it could sell the business to Coloplast, speaking on the sidelines at the JPMorgan Healthcare conference in San Francisco on January 12, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COLOB:DC kr519.50 DKK -11.50

COLOB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $167.18 USD -1.12
Smith & Nephew PLC 1,131 GBp -68.00
Teleflex Inc $122.41 USD -0.50
William Demant Holding A/S kr554.50 DKK -2.50
View Industry Companies

Industry Analysis


Industry Average

Valuation COLOB Industry Range
Price/Earnings 43.5x
Price/Sales 8.2x
Price/Book 19.2x
Price/Cash Flow 41.3x
TEV/Sales 7.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLOPLAST-B, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at